VBI Starts Phase 1 Study of Multivalent Coronavirus Vaccine

 

• Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses
• Preclinical data support broadly reactive immunity of VBI-2901 against a panel of coronavirus variants in mice, which now also includes circulating BA.4 and BA.5
• The study is expected to enroll approximately 100 adults in Canada and is supported by the Government of Canada
• Interim data expected mid-year 2023, subject to speed of enrollment

https://www.biospace.com/article/releases/vbi-vaccines-announces-initiation-of-phase-1-study-of-multivalent-coronavirus-vaccine-candidate-vbi-2901/